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Abstract
Background: Melanoma is the most fatal skin cancer displaying a high degree of molecular heterogeneity.
Phenotype switching is a mechanism that contributes to melanoma heterogeneity by altering transcription profiles
for the transition between states of proliferation/differentiation and invasion/stemness. As phenotype switching is
reversible, epigenetic mechanisms, like DNA methylation, could contribute to the changes in gene expression.
Results: Integrative analysis of methylation and gene expression datasets of five proliferative and five invasion
melanoma cell cultures reveal two distinct clusters. SOX9 is methylated and lowly expressed in the highly proliferative
group. SOX9 overexpression results in decreased proliferation but increased invasion in vitro. In a B16 mouse model,
sox9 overexpression increases the number of lung metastases. Transcriptional analysis of SOX9-overexpressing
melanoma cells reveals enrichment in epithelial to mesenchymal transition (EMT) pathways. Survival analysis of
The Cancer Genome Atlas melanoma dataset shows that metastatic patients with high expression levels of SOX9
have significantly worse survival rates. Additional survival analysis on the targets of SOX9 reveals that most SOX9
downregulated genes have survival benefit for metastatic patients.
Conclusions: Our genome-wide DNA methylation and gene expression study of 10 early passage melanoma cell
cultures reveals two phenotypically distinct groups. One of the genes regulated by DNA methylation between the
two groups is SOX9. SOX9 induces melanoma cell invasion and metastasis and decreases patient survival. A number of
genes downregulated by SOX9 have a negative impact on patient survival. In conclusion, SOX9 is an important gene
involved in melanoma invasion and negatively impacts melanoma patient survival.
Background
Melanoma is an aggressive skin cancer that originates
from melanocytes, that is, pigment cells that reside in
the basal layer of the epidermis and are derived from the
neural crest during early development [1]. It is the most
life-threatening neoplasm of the skin and is considered a
major health problem due to rising incidence and mor-
tality rates [2,3]. Melanoma is a tumor with a high de-
gree of heterogeneity and this phenotypic heterogeneity
is reversible [4-7]. In addition to being a challenge for
basic research, melanoma plasticity is a major hurdle for
successful treatment [8]. Investigating the molecular
basis of phenotypic heterogeneity is crucial to better
understand melanoma progression and should provide
useful insights for the development of more effective
therapies.
In an effort to elucidate the molecular mechanisms of
melanoma progression, significant differences have been
detected between melanoma cells from the same lesion
[4,6,9]. We and others have found that melanoma cells
generally express two distinct gene expression signatures,
that these signatures correlate with in vitro characteristics
and these phenotypes are reversible depending on their
cellular microenvironments [10-12]. One signature is
characterized by the upregulation of several melanocytic
genes like MITF, TYR, and DCT. These melanoma cells
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are highly proliferative and weakly invasive in vitro and so
are named the proliferative phenotype. The other signature
is characterized by the upregulation of many mesenchymal
genes such asWNT5A,TGFβ, and FGF2. In contrast to the
proliferative cells, these cells are highly invasive but have a
low proliferative capacity in vitro and are thus named the
invasive phenotype. Meta-analysis of all available melanoma
microarray datasets available on the NCBI GEO database
confirmed these two gene signatures in 86% of the 536
melanomas [13]. Immunohistochemical analyses of MITF
and WNT5A, markers of the proliferative and invasive
phenotype, respectively, of human primary and metastatic
melanomas displayed an anti-correlative staining pattern
confirming that these phenotypes exist in vivo [14]. To-
gether these findings culminated in the phenotype switch-
ing model for melanoma progression, in which melanoma
cells respond to changing micro-environmental signals,
such as hypoxia, by reprogramming their gene expression
patterns to switch between states of proliferation and inva-
sion [9,15]. Thus, phenotype switching has important im-
plications in melanoma progression. Invasive phenotype
cells characterized by low MITF expression, have stem-like
properties [16], including the ability to initiate tumors with
high efficiency [17]. Consequently, tumors comprise a mix
of MITF positive and negative melanoma cells [18].
DNA methylation provides a stable and heritable gene
regulatory mechanism for which melanoma cells could
alter the expression of many genes [19]. Aberrant DNA
methylation is a mechanism known to cause tumorigen-
esis [20]. Tumor suppressor genes become silenced by
hypermethylation of their promoter region, thus promot-
ing tumorigenesis. Global hypomethylation has been ob-
served in many cancers, including melanoma, to decrease
with progression of the disease [21-23]. DNMT3a and
DNMT3b, the de novo DNA methyltransferases, were
shown to have increased expression in metastatic melano-
mas compared to primary melanomas [24]. Another group
showed that DNMT3a is required for melanoma develop-
ment and metastasis in a melanoma mouse model [25].
Several signaling pathways have been shown to be deregu-
lated as a result of aberrant DNMT-dependent methyla-
tion in melanoma, which include MAPK, WNT, PI3K,
pRB, and pathways in cell cycle, apoptosis, invasion, and
metastasis [26]. Progressive global DNA hypomethylation
has been observed in malignant melanocyte transform-
ation, and surprisingly transformation was blocked in the
presence of 5-Aza-2-deoxycytidine (decitabine, Aza),
a DNMT inhibitor [22]. It would suggest that targeted
hypomethylation is required for malignant transform-
ation and not overall global hypomethylation caused by
Aza treatment. This is supported by our observation
that treating proliferative melanoma cells with Aza had
no measureable effect on their invasive abilities (data
not shown). 5-Aza-2-deoxycytidine treatment of various
melanoma cell lines was shown to increase SOX9 ex-
pression and induce expression of p27 and p21 [27].
SOX9 is a transcription factor involved in neural crest
specification [28] and SOX9 overexpression in melan-
oma cell lines have been shown to induce cell cycle
arrest in a p21 dependent manner [29]. Taken together,
it would suggest that DNA methylation has a crucial
role in malignant transformation and progression by
altering the landscape of the methylome to promote
tumor progression, and SOX9 is one of the targets of
DNA methylation that induces cell cycle arrest.
In this study, we examine the expression of the DNMTs
between the proliferative and invasive melanoma cell
cultures and describe the differential melanoma methy-
lome by MeDIP-chip. We confirm that SOX9 expres-
sion is regulated by DNA methylation and has a role in
cell cycle regulation, invasion in vitro and in vivo and
could be a prognostic marker for overall survival in
metastatic melanoma patients.
Results
Proliferative melanoma cells have higher levels of global
DNA-methylation
We have previously established melanocytic markers like
MLANA to distinguish between the proliferative and
invasive phenotype on a cohort of primary melanoma cell
cultures (Additional file 1: Figure S1) [11,30]. To investigate
if methylation differences exist between the proliferative
and invasive melanoma phenotypes, we compared five
proliferative (M000921, M010817, M080423, M980513,
and M050829) and five invasive (M990115, M010119,
M080201, M080307, and M080310) melanoma cell cul-
tures for expression of de novo DNA methyltransferases
DNMT1, 3a, and 3b (Figure 1A). We observed that the
invasive phenotype melanoma cell cultures had about
51.1% less expression of DNMT1 as compared to the pro-
liferative phenotype melanoma cell cultures (Figure 1A).
DNMT3b had about 50% less protein expression in the
proliferative melanoma cell cultures compared to the
invasive melanoma cell cultures (Figure 1A). However,
DNMT3a was not differentially expressed between the
proliferative and invasive phenotype (Figure 1A). Global
methylation analysis by methyl-cytosine ELISA showed
that the invasive phenotype cells have significantly less
DNA methylation in their genome compared to the
proliferative phenotype cells, 13.0% to 20.9%, respectively
(Figure 1B). This raises the possibility that differential
methylation exists between the proliferative and invasive
phenotype.
A 73-gene signature is significantly differentially methylated
and expressed in proliferative melanoma cells
The difference in global methylation levels and protein
expression of DNMT1 and DNMT3b prompted us to
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investigate the methylation profiles of the proliferative and
invasive phenotype melanoma cells. To determine which
CpG islands were differentially methylated between the
proliferative and invasive phenotypes, we immunopreci-
pitated methylated DNA from five proliferative and five
invasive melanoma cell cultures by MeDIP [31] followed
by hybridization to Nimblegen Human DNA Methylation
3x720K CpG Island Plus RefSeq Promoter Arrays. This
array contains 720,000 probes for 22,532 promoter regions
and 27,728 CpG islands. We calculated the differential
Figure 1 Phenotype specific expression of DNMTs and DNA methylation patterns. (A) Western blot for DNMT1 and DNMT3a and DNMT3b
on five proliferative phenotype and five invasive phenotype cell lysates. GAPDH was used as a loading control. Optical density of each band was
measured and normalized to GAPDH intensity. (B) Global methylation analysis by ELISA for methyl-cytosine on five proliferative cell cultures and
five invasive cell cultures. There was a significant difference (P <0.05, Student’s t-test) in global methylation between the proliferative and invasive
phenotype melanoma cells. (C) Heat map representing the 406 gene promoters differentially methylated between the proliferative and invasive
phenotype cultures. (D) Heat map representing the top 250 genes differentially expressed between the proliferative and invasive phenotype.
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methylation levels between the five proliferative and five
invasive melanoma cells with a sliding window ANOVA
test with the R package DMR supplied from Nimblegen.
We found 406 gene promoters to be significantly and
differentially methylated between the proliferative and
invasive phenotypes (Figure 1C). A total of 320 pro-
moter regions were hypermethylated in the proliferative
phenotype and 86 promoter regions were hypermethy-
lated in the invasive phenotype. The greater number of
hypermethylated regions in the proliferative phenotype
would be consistent with the global methylation data.
Gene expression data for the 10 melanoma cell cultures
previously generated by us [13] were reanalyzed for differ-
ential gene expression between the proliferative and inva-
sive phenotypes using the R package limma [32]. A total of
1,750 genes were differentially expressed between the pro-
liferative and invasive phenotype (fold change >2, FDR cor-
rected P <0.05) (Figure 1D). We then analyzed the
relationship between the promoter methylation status and
mRNA expression levels for all genes in both datasets.
Genes were filtered for a peak score >2 for methylation,
fold change >2 for gene expression and an FDR-corrected P
value <0.05. A total of 73 genes showed both significant
differential DNA methylation and significant differential
expression between the proliferative and invasive pheno-
type (Additional file 2: Table S1). Sixty-two genes from
the proliferative phenotype had hypermethylated pro-
moters and low RNA expression and 11 genes in the in-
vasive phenotype had hypermethylated promoters and
low RNA expression as compared to the proliferative
phenotype. This suggests that methylation has a role in
regulating a portion of the genes differentially expressed
between the proliferative and invasive phenotype. We hy-
pothesized that the 73 genes with both differential DNA
methylation and mRNA expression between the prolifer-
ative and invasive melanoma cells were likely to be true
targets of epigenetic regulation in melanoma. To deter-
mine which groups of genes were functionally import-
ant, we performed pathway analysis of the 73 genes on
MetaCore. We looked for enrichment of pathways
under GO processes, process networks, and Pathway
maps (Additional file 3: Table S2). Interestingly, we ob-
served significant enrichment in pathways involved in
EMT, melanoma, and cell differentiation. We decided to
focus on SOX9 for validation due to its known function
in melanocyte differentiation and melanoma progres-
sion [29,33,34].
Sox9 expression is silenced in proliferative melanoma
cells through promoter DNA methylation
From the methylation array, the area that had the most en-
richment for methylation was about 2 kb upstream of the
SOX9 transcriptional start site thus we validated the CpG
island located there via sequencing of bisulfite-treated
genomic DNA in the 10 melanoma cell cultures (Figure 2A).
There are three predicted transcription factor binding sites
in that upstream promoter region of SOX9 for MEF2, E2F,
and HNF3B. We analyzed the DNA methylation status of a
cluster of 17 CpGs across a 283-bp region and 15 CpGs
across a 256-bp region of a CpG island, located approxi-
mately −2,500 bp to −2,000 bp upstream of the SOX9 tran-
scriptional start site. The majority of CpGs in both
regions of the SOX9 promoter were consistently meth-
ylated in the proliferative phenotype melanoma cell
cultures and consistently unmethylated in the invasive
phenotype melanoma cell cultures.
To confirm that promoter DNA hypermethylation cor-
related with transcriptional silencing of SOX9, we assessed
mRNA levels using real-time RT-PCR in the 10 melanoma
cell cultures. SOX9 mRNA was expressed robustly in
the invasive phenotype melanoma cell cultures com-
pared to the proliferative phenotype melanoma cell cul-
tures (P <0.05) (Figure 2B). Protein expression of SOX9
was detected in all invasive phenotype melanoma cell
lysates, but little to no expression of SOX9 was seen in the
proliferative phenotype melanoma cell lysates (Figure 2C).
To validate that SOX9 is indeed regulated by DNA methy-
lation, we treated the five proliferative phenotype mel-
anoma cell cultures with 5 μM 5-Aza-2′-deoxycytidine
(a DNMT inhibitor) for 72 h. Re-expression of SOX9
was detected by western blot (Figure 2D). Thus, SOX9
expression is regulated by DNA methylation between
the proliferative and invasive phenotype.
SOX9 mediates proliferation and invasion in melanoma
cell cultures
SOX9 is expressed in the invasive phenotype and we
have previously described the greater invasive potential
of invasive versus proliferative phenotype melanoma
cells [30,35]. We hypothesized that some of the differen-
tially expressed genes could have a role in generating this
invasive capacity, thus we wanted to see if SOX9 would
have a role in invasion. SOX9 was knocked down with
siRNA, and then the invasive ability of two invasive pheno-
type melanoma cell cultures was measured: M080201 and
M080310. Treatment with two independent siRNAs for
SOX9 achieved about 70% knockdown of SOX9 mRNA
in M080201 and M080310 (Figure 3A). The invasive
capacity of M080201 and M080310 decreased signifi-
cantly (P <0.05) from 30% to 11.5% and from 64.8%
to 36.6%, respectively, after 48 h treatment with siRNA
targeting SOX9 (Figure 3B and C). Proliferation was
unaltered from SOX9 knockdown (data not shown).
Consistent with this observation, we overexpressed
SOX9 in proliferative phenotype melanoma cell cultures
(that is, M010817 and M980513) by lentiviral transfec-
tion (Figure 3D). Overexpression of SOX9 was previously
shown to drive melanoma cells into cell cycle arrest [29].
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We measured proliferation and cell cycle progression by
EdU and PI staining, respectively, and observed the cells
transfected with vector have 50.5% in G1 phase, 37% in
S phase, and 12.5% in G2/M phase, whereas the cells
overexpressing SOX9 have 64.8% in G1 phase, 17.7% in S
phase, and 17.5% in G2/M phase (P <0.05) (Figure 3E
and F). The invasive capacity of M010817 and M980513
were significantly increased from 0.95% to 9.0% (P <0.05)
and from 0.67% to 4.8% (P <0.05) from SOX9 overexpres-
sion (Figure 3G and H). In concordance with previously
published data on SOX9 in melanoma, we also see G1/G0
arrest when SOX9 is overexpressed along with increased
invasion.
SOX9 induces a partial invasive phenotype in proliferative
melanoma cells
To determine the effect of SOX9 overexpression on the
proliferative phenotype, we performed microarray analysis
of M010817 cells overexpressing SOX9. We detected 643
genes downregulated at least two-fold and 450 genes up-
regulated at least two-fold (P <0.05 (Figure 4A, Additional
file 4: Table S3). We overlapped the gene signature from
the SOX9 overexpression microarray with the gene sig-
nature from the 10 melanoma cell culture microarray to
ask if SOX9 induced genes are enriched in the invasive
phenotype. There were 98 genes that were upregulated
and 55 genes that were downregulated in both the
SOX9 overexpression and invasive phenotype gene sets.
Hypergeometric distribution of the overlap of the SOX9
microarray with 10 melanoma cell culture array was
significant (P <0.001) (Figure 4B). Thus, SOX9 appar-
ently regulates about 10% of the genes that define the
invasive phenotype gene set. This suggests that SOX9
activation contributes to the invasive phenotype but
other factors are also required for the full transition.
In vivo function of SOX9 overexpression
To examine the effects of SOX9 in vivo, we utilized the
B16F1 mouse melanoma cells which do not express sox9
and are known not to metastasis in a tail vein injection
assay. We transfected murine sox9 transiently into the
B16F1 cells and monitored its expression over 288 h.
Expression of sox9 decreases over time but protein is
still detectable at 288 h (Figure 5A). To assess the in vivo
Figure 2 Validation of SOX9 methylation. (A) Lollipop diagrams of bisulphite sequencing of SOX9 promoter. Black lollipops are methylated
CpGs; white lollipops are unmethylated CpGs. A minimum of five clones were sequenced for each cell culture. (B) mRNA expression of SOX9
normalized to the housekeeping gene RPL28 across 10 melanoma cell cultures. Results are presented as mean +/− s.d., n = 3. Statistical significance of
differential expression between the proliferative and invasive phenotype cell cultures was determined by Student’s t-test. (C) Western blot for SOX9 in
10 melanoma cell cultures. GAPDH served as loading control. (D) Western blot for SOX9 of five proliferative melanoma cell cultures treated with
5-aza-2-deoxycytidine (Aza).
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metastatic potential of sox9, C57BL/6 J mice were intra-
venously injected with B16F1 cells transfected with sox9
and empty vector (Figure 5B). Twelve days after injection,
the mice were sacrificed and the lungs were analyzed for
tumor nodules. B16F1 cells expressing sox9 had signifi-
cantly more metastases compared to control, P <0.05.
Validation with TCGA melanoma dataset
The Cancer Genome Atlas (TCGA) has a melanoma
dataset available for public access which contains over
300 tissue samples with RNAseq, DNA methylation,
and clinical data. To validate our claim that SOX9 is
regulated by DNA methylation, we performed a correl-
ation analysis of SOX9 expression to SOX9 promoter
methylation using the data from the TCGA database.
Three consecutive probes cg10471574, cg21049501,
and cg06234051 in the SOX9 promoter region have an
anti-correlative association with the expression of SOX9,
r = −0.58, −0.61, and −0.71 respectively (Figure 6A). Since
high DNA methylation of SOX9 is correlated with low
SOX9 expression it provides strong evidence that DNA
methylation regulates SOX9 expression in vivo.
The melanoma dataset contains 68 primary samples
and 268 metastatic samples. The 268 metastatic samples
Figure 3 SOX9 mediates invasion and cell cycle arrest. (A) SOX9 knockdown by siRNA in two melanoma cell cultures M080201 and M080310.
(B) Boyden chamber assay for siSOX9 knockdown in M080201 and M080310. (C) Representative picture of the Boyden chamber assay for knockdown
of SOX9 in M080310. Top panel shows M080310 cells treated with control siRNA (siCtrl). Bottom panel shows M080310 cells treated with siSOX9_1.
(D) SOX9 overexpression by lentiviral expression in proliferative phenotype melanoma cell cultures M010817 and M980513. (E) Proliferation
assay by EdU pulse in cell cultures transfected with empty vector and pLenti-SOX9. (F) Cell cycle analysis by PI staining for cell cultures transfected with
empty vector and pLenti-SOX9 (top and bottom left panels). Quantitation of cell cycle analysis (* = P <0.05, right panel). (G) Boyden chamber assay for
SOX9 overexpressing melanoma cell cultures M010817 and M980513 (* = P <0.05). (H) Representative picture of the Boyden chamber assay for SOX9
overexpression in M010817. Top panel shows M010817 transfected with empty vector. Bottom panel shows M010817 transfected with SOX9.
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are comprised with 172 lymph node tumors, 59 regional
cutaneous or subcutaneous metastases, and 37 distant
metastases. Due to the diversity of this dataset we ana-
lyzed the primary and metastatic samples individually.
We segregated the population into thirds by SOX9
expression. We compared the upper and lower thirds for
our analysis labelling them SOX9 high and SOX9 low. In
both primary and metastatic datasets, the SOX9 high
group had at least three times more expression than the
SOX9 low group. We interrogated clinically relevant
factors such as TNM staging, age, gender, and tumor
type between the SOX9 high and SOX9 low group in the
primary and metastatic datasets (Table 1, Additional file 5:
Table S4). All parameters were statistically insignificant as
tested by the Chi-squared test and t-test for age in the
primary melanoma dataset. Only two clinical parame-
ters were significant in the metastatic dataset. T1 was
significant 2 vs. 11 (P = 0.013) in the SOX9 low versus
SOX9 high, respectively. N0 was also significant 26 vs. 44
(P = 0.031) in the SOX9 low versus SOX9 high, respectively.
We next tested if the genes differentially expressed be-
tween the SOX9 high and SOX9 low patients in the pri-
mary and metastatic datasets were the same in our SOX9
overexpression microarray. A total of 21 genes were differ-
entially expressed between the SOX9 high and SOX9 low
groups in the primary dataset with a minimum fold
change of 2 and FDR corrected P value <0.05 (Additional
file 6: Table S5). No genes from this set overlapped with
the SOX9 microarray. A total of 427 genes were differen-
tially expressed between the SOX9 high and SOX9 low
groups in the metastatic dataset with a minimum fold
change of 2 and FDR corrected P value <0.05 (Figure 6B,
Additional file 7: Table S6). A total of 31 genes overlapped
with the SOX9 microarray. Although the overlap was
small, hypergeometric distribution of this overlap was
significant (P <0.05). To examine the pathways in which,
SOX9 might play a role in vivo, we performed pathway
analysis on the 427 genes. We saw significant enrichment
of many EMT pathway processes such as ‘Regulation of
epithelial-to-mesenchymal transition (EMT)’, ‘TGF-beta
dependent induction of EMT via SMADs’, and ‘Melano-
cyte development and pigmentation’ (Figure 7A).
We interrogated if SOX9 has a role in overall patient
survival in all patients regardless of primary or meta-
static disease. There was a significant difference in
10-year survival rates between the SOX9 high and SOX9
low groups. SOX9 high patients had a median survival
rate of 3.9 years whereas the SOX9 low patients had a
median survival time of 5.8 years (P <0.05) (Figure 7B).
Cox multivariate analysis was carried out to identify if
age, gender, TNM stage, and tumor type were significant
contributing factors for 10-year survival of SOX9 high and
SOX9 low patients. SOX9 expression (hazard ratio 2.343;
95% confidence interval (CI) 1.402-3.915; P = 0.001; SOX9
Figure 4 Microarray analysis of SOX9 overexpression. (A) Heat map of M010817 cells overexpressing SOX9. (B) Overlap of upregulated genes
and downregulated genes between the SOX9 microarray and 10 melanoma cell culture microarray.
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high vs. SOX9 low) and T4 stage (hazard ratio 2.145;
95% CI 1.01-4.557; P = 0.047; T4 vs. T0) were significant
(Table 2). We also segregated the patients into primary,
lymph node, metastasis and regional/distant metastasis
and reassessed survival based on SOX9 expression. We
saw that SOX9 expression in primary tumors had no
effect on patient survival. However, the cohort of
patients with high SOX9 expression in lymph nodes had
significantly lower survival (P = 0.03), as in the regional/
distant metastasis cohort (P = 0.01) (Figure 7C).
We tested all 31 overlapping genes for survival benefit
in the metastatic dataset (Additional file 8: Table S7).
Twelve of the genes of this set were upregulated and 19
were downregulated when SOX9 expression was high.
Most of the genes, 92% (11/12), that were upregulated
when SOX9 expression is high had no influence on
patient survival, only one gene 7% (1/12) was associated
with improved survival (Figure 7D). This suggests that
the genes upregulated by SOX9 are not direct factors for
patient survival. Interestingly, 58% (11/19) of the genes
downregulated when SOX9 expression is high were
associated with improved survival and the other 42%
(8/19) had no influence on patient survival (Figure 7D).
This suggests that SOX9 represses a group of genes
important for patient survival. Taken together, high
SOX9 expression leads to poor survival possibly due to
the downregulation of several genes that influence
patient survival.
SOX9 binds to the promoter regions of its target genes
Using the SOX9 binding motif to screen for potential
binding sites on the promoter regions from the 31 over-
lapping targets of the SOX9 microarray and the TCGA
melanoma dataset, we found 19 of the 31 genes had a
potential SOX9 binding site within a 3 kb region up-
stream from the TSS. To determine whether SOX9
directly binds to the promoter regions of these genes, we
performed ChIP analysis using SOX9 antibodies on
Figure 5 In vivo function of sox9 overexpression. (A) Western blot analysis of transient sox9 overexpression in B16F1 up to 12 days.
(B) Representative pictures of B16F1 cells intravenously injected into C57BL/6 J mice 12 days after injection (n = 5 mice per group). Quantification
(right graph). * = P <0.05 Mann–Whitney U test.
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M010817-SOX9 cells and measured SOX9 occupancy at
promoter regions of TMEM158, TBX3, and FYB, for which
we could design specific primers for qPCR (Figure 7E).
The specificity of this assay was demonstrated by the en-
richment of three known SOX9 target sequences, COL2A1
intron 1 [36], p21 [29], and SOX10 [37]), as compared to a
non-target gene (IP10). We observed a specific association
of SOX9 with TMEM158, TBX3, and FYB, suggesting
that TMEM158, TBX3, and FYB are direct targets of
SOX9 in melanoma.
Discussion
Phenotypic, genetic, and epigenetic heterogeneity is a
common feature in human melanomas [4,5,14,38]. Tumor
subpopulations can be transient and have been seen to
switch between phenotypic states in vivo [4,6,9,12,39].
We have previously described two subpopulations in
melanoma, the proliferative phenotype and the invasive
phenotype, which are defined by specific gene signatures,
in vitro characteristics, and response to drug treatment
[11,13,30,35,40]. Briefly, proliferative phenotype melanoma
cells are distinguished by a high proliferative capacity and
low invasive capacity and the invasive phenotype melan-
oma cells are distinguished by a low proliferative capacity
and high invasive capacity. In this study, we found specific
DNA methylation signatures for the proliferative and
invasive melanoma phenotypes. We observed the inva-
sive phenotype melanoma cell cultures had modest
decrease of 5% in global methylation compared to the
proliferative phenotype melanoma cell cultures. This
may be due to decreased DNMT1 protein expression in
the invasive phenotype melanoma cells. Global methyla-
tion levels have been observed to decrease as a cancer-
ous lesion progresses from a benign tumor to metastasis
[22,41], and we observed our invasive phenotype melan-
oma cell cultures had decreased DNA methylation levels
and were more invasive than the proliferative phenotype
melanoma cell cultures, suggesting the invasive cell
Figure 6 Validation of SOX9 methylation in TCGA and correlation with clinical features. (A) Correlation plots of RNAseq reads to b-values
of methylation for SOX9. Three methylation probes of SOX9 are shown here to have significant anti-correlation of gene expression and DNA
methylation. (B) Heatmap of the 427 genes differentially expressed between the SOX9 high and SOX9 low metastatic melanoma samples.
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cultures have progressed further in malignancy. Differ-
ential expression of the de novo DNA methyltransferase
DNMT3b was also seen between the proliferative and
invasive phenotype. These data are consistent with a
model in which DNMT1 and DNMT3b have phenotype
specificity and contribute to transcriptional heterogeneity
by altering the methylation landscape of a melanoma cell
in the context of melanoma phenotype switching. Pathway
analysis of the 73 gene signature from the DNA methyla-
tion and gene expression array lead to the discovery of
many transcription networks involved in development.
These transcription factors were found to be hypomethy-
lated and highly expressed in the invasive phenotype,
which would suggest the invasive melanoma cell cultures
may revert to a dedifferentiated state.
A number of other studies that have looked at genome-
wide DNA methylation in melanoma have indicated that
several tumor suppressors are silenced by DNA methyla-
tion compared to normal melanocytes [42-44] and
compared to benign nevi [45]. Also, a recent study in-
vestigating 5-hydroxymethylation (5-hmC) in melanoma
found a global decrease of 5-hmC was necessary for
melanoma formation [46]. The results from these studies
indicate aberrant DNA methylation is an important
process in melanoma development and progression. In
our work, we looked at the differences in DNA methy-
lation landscape between 10 primary melanoma cell
cultures and uncovered two distinct populations, as pre-
viously demonstrated by gene expression microarray
analysis from our group [13]. Surprisingly, the targets
we found to be differentially methylated between the
two phenotypes do not overlap with the targets found
to be differentially methylated between normal melano-
cytes and melanoma, and benign nevi and melanoma.
We did not detect any differential methylation in vali-
dated methylation gene sets such as COL1A2, NPM2,
HSPB6, DDIT4L, and MTIG from Koga et al. [43] or
UCHL1, COL1A2, THBS1, and TNFRSF10D from Bonazzi
et al. [42]. As those studies were comparing the methyla-
tion state of normal melanocytes to melanoma and in this
study we compare within melanoma phenotypes, this
might indicate that a different set of pathways are acti-
vated or silenced by DNA methylation in melanoma
progression compared to melanoma initiation. In either
case, it is clear that epigenetic modifications such as
DNA methylation play an important role in melanoma
initiation as well as progression, and embryonic devel-
opmental program reactivation may be one of the
critical outcomes of this modulatory activity.
In our study, a subset of our melanoma cell cultures
had lower SOX9 expression due to a hypermethylated
promoter and the other subset with high SOX9 expres-
sion had a hypomethylated promoter. We confirmed
that SOX9 is regulated by DNA methylation by treating
low SOX9 expressing cells with 5-aza-2-deoxycytidine
treatment and saw re-expression of SOX9. To determine
if the regulation of SOX9 by DNA methylation is a com-
mon mechanism in melanoma or just seen within our
melanoma cell cultures, we interrogated the melanoma
TCGA dataset for SOX9 and found that SOX9 gene
expression and DNA methylation are anti-correlated at
three consecutive methylation probes in 293 samples.
This provides strong evidence that specific DNA methy-
lation is the molecular mechanism that regulates SOX9
expression in melanoma. Alcazar et al. demonstrated that
after decitabine treatment of A375 and B16 melanoma
cells, the promoter of SOX9 becomes hypomethylated and
SOX9 is re-expressed with induction of p27 and p21 for
cell cycle arrest [27]. Passeron et al. also observed that
SOX9 was downregulated in some melanoma cell lines
and induction of SOX9 expression in these melanoma cell
lines resulted in lower proliferation due to upregulation
of p21 [29]. We also overexpressed SOX9 in low SOX9
melanoma cell cultures and observed G1/S cell arrest,
which is consistent with the study from Passeron et al.
Although the proliferation rate is reduced, the invasive
capacity of these SOX9 overexpressing cells is increased,
which phenocopies the endogenous SOX9 expressing
Table 1 Clinical parameters of metastatic melanoma
patients
Clinical parameter SOX9 low SOX9 high p value
T0 15 13 0.706
T1 2 11 0.013 *
T2 17 17 1
T3 20 13 0.223
T4 16 16 1
N0 26 44 0.031 *
N1 16 9 0.162
N2 15 9 0.221
N3 12 9 0.513
NX 1 0 1
M0 67 64 0.793
M1 2 6 0.157
Female 29 25 0.586
Male 45 49 0.68
Lymph node 48 49 0.919
Regional cutaneous or
subcutaneous metastasis
17 14 0.59
Distant metastasis 9 11 0.655
Age 57 59.9 0.213a
TNM stage, gender, and tumor location between the SOX9 high and SOX9
low patients were evaluated by the Chi-squared test.
aAge was evaluated by Student’s t-test.
*P <0.05.
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cells. Conversely, knockdown of SOX9 in the invasive
phenotype melanoma cells reduced the invasive capacity
of the cells. Microarray analysis of SOX9 overexpression
revealed an EMT-like transcriptional signature and had
10% overlap with invasive phenotype gene signature which
supports the notion that SOX9 is a factor that contributes
to the invasive phenotype. In vivo, sox9 expression in
B16F1 cells increases their metastatic potential causing
more tumor lung nodules in the tail vein injection assay.
Taken together, SOX9 is a gene that is regulated by DNA
methylation and functionally, SOX9 mediates cell cycle
progression, invasion, and metastasis in melanoma.
TCGA is a great resource for clinical and next-
generation sequencing data on human tumors. We
Figure 7 TCGA analysis of SOX9. (A) Pathway analysis from MetaCore for SOX9 reveals many pathways involved in EMT. (B) Median survival
time for patients with high SOX9 expression is 3.9 years (n = 74). Median survival time for patients with low SOX9 expression is 5.8 years (n = 74).
The difference in survival is significant (P <0.05). (C) Survival analysis for high and low SOX9 expression segregated into primary, lymph node, and
metastatic cohorts. (D) Pie charts displaying the number of SOX9 target genes that have a contribution to patient survival. (E) ChIP analysis for
SOX9 binding targets. Enrichment of the promoter regions for TMEM158, TBX3, and FYB were similar to positive controls COL2A1, p21, and
SOX10 and greater than negative control IP10. Data are shown as bound vs. input. Error bars indicate standard error of the mean of three
independent experiments. IgG controls not shown on graph because they were below detection limit.
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took advantage of the melanoma dataset and demon-
strated that SOX9 expression levels have a significant
impact on survival of metastatic melanoma patients
but SOX9 did not have a significant impact on survival
in patients with primary melanomas. This could sug-
gest that SOX9 is required for progression of primary
melanoma into metastasis and metastatic tumors with
high SOX9 are more aggressive to the patient. There
were no clinical metrics that could distinguish SOX9
high or low in primary melanoma. Only T1 and N0
stage in metastatic melanomas were significant be-
tween SOX9 high and low. Survival analysis of meta-
static patients with high SOX9 expression versus low
SOX9 expression revealed a significant difference in
the overall 10-year survival rates. Patients with high-
SOX9 expressing tumors had a 2.3 times increased risk
of death compared to patients with low SOX9 express-
ing tumors. Based on these findings and the invasive
properties of high SOX9 expressing melanomas, it
would suggest that SOX9 expression in melanomas
could push the tumor toward more aggressive metasta-
sis. Thus, SOX9 could potentially be a prognostic
marker for metastatic melanoma.
We performed differential gene expression analysis
on the RNAseq dataset where we defined the SOX9
high group as having a minimum of three-fold greater
expression than the SOX9 low group. We only saw an
overlap of 31 genes between both datasets; however,
the overlap was significant as determined by hypergeo-
metric distribution. The contribution of heterogeneity
in the melanoma TCGA patient population would be
one of the largest factors for the difference in gene sig-
natures between our SOX9 microarray and TCGA
RNAseq data. Nonetheless, the significant overlap of
genes narrow down the potential targets of SOX9. To
confirm that the targets of SOX9 have prognostic value
for the patients, we performed survival analysis on all
31 genes. Surprisingly, 58% (11/19) of the genes down-
regulated by SOX9 were associated with improved sur-
vival, which strongly suggests SOX9 represses a set of
genes that decrease tumor malignancy. Genes that
were upregulated by SOX9 expression had little impact
on patient survival which implies that SOX9 expres-
sion alone is sufficient to drive disease progression.
From this list of 31 genes, 19 of them had a potential
SOX9 binding site in its promoter. We could validate
TMEM158, TBX3, and FYB as direct targets of SOX9
binding by chromatin immunoprecipitation. FYB is
downregulated when SOX9 levels are high suggesting a
repressive effect of SOX9 on this gene. FYB is required
for inflammatory cytokine production [47] but no
known link has been established with melanoma.
TMEM158 is upregulated by SOX9 but no clear role
has been established for the gene in melanoma. TBX3
is also upregulated by SOX9 and TBX3 is known to
cause increased invasiveness in melanoma [48,49],
suggesting TBX3 could be an effector gene that drives
the invasive phenotype we see in SOX9 high cells and
in patients.
Conclusion
In conclusion, we found SOX9 to be regulated by
DNA methylation, and high SOX9 expression leads to
poor survival in melanoma patients due to the activa-
tion of EMT-like genes and the downregulation of
potential tumor suppressor genes in melanoma cells.
This was confirmed in vivo, and new direct targets of
SOX9 that may mediate its function in tumor pro-
gression were identified by transcriptional profiling
and chromatin-immunoprecipitation. Future therapies
targeting SOX9 could be beneficial for patients to
prevent progression and especially when combined with
therapies targeting cells of the proliferative phenotype.
Further investigation would be required to determine if
SOX9 would have early prognostic value for tumor
malignancy.
Table 2 Multivariate cox regression on metastatic
melanoma patients
Covariate HR Lower 95% Upper 95% p-value
SOX9 (SOX9 low = 0,
SOX9 high =1)
2.343 1.402 3.915 0.001***
Age 0.995 0.977 1.103 0.59
Gender (female = 0,
male =1)
0.756 0.457 1.25 0.276
T0 (used as reference)
T1 0.431 0.117 1.598 0.208
T2 0.943 0.416 2.138 0.888
T3 1.022 0.489 2.132 0.955
T4 2.145 1.01 4.557 0.047*
N0 (used as reference)
N1 1.673 0.813 3.446 0.162
N2 1.365 0.673 2.771 0.388
N3 1.322 0.574 3.044 0.512
M0 (used as reference)
M1 2.023 0.672 6.09 0.21
Lymph Node (used as
reference)
Regional Cutaneous or
Subcutaneous Metastasis
0.844 0.452 1.577 0.595
Distant Metastasis 1.83 0.957 3.499 0.068
SOX9 expression, age, gender, TNM stage, and tumor location were evaluated
in a multivariate cox regression model. Hazard ratio (HR) and the 95% CIs are
displayed for each covariate.
*P <0.05.
***P <0.001.
Cheng et al. Genome Biology  (2015) 16:42 Page 12 of 16
Materials and methods
Cell culture
Melanoma cell cultures were established from surplus
material from primary cutaneous melanoma and mel-
anoma metastases removed by surgery [50]. Written
informed consent was approved by the local IRB
(EK647 and EK800). Clinical diagnosis was confirmed
by histology and immunohistochemistry. Melanoma
cells were released from tissue biopsies and grown as
previously described [51]. Melanoma cell cultures
were maintained in RPMI (Invitrogen, Carlsbad, CA,
USA) supplemented with 5 mM glutamine, 1 mM
sodium pyruvate, and 10% heat-inactivated fetal calf
serum, and cultured at 37°C and 5% CO2. As RNA
was extract previously from these cell cultures for
gene expression array analysis, all cell cultures used
for experiments in this paper were within five pas-
sages of the RNA isolation time point.
5-methylcytosine relative content analyses
Global DNA methylation level was evaluated by Methyl-
Flash Methylated DNA Quantification Kit (Epigentek,
Farmingdale, NY, USA) as per manufacturer’s instructions.
MeDIP assay and analysis
The MeDIP assay was performed as described [31]. A
monoclonal antibody to 5-Methylcytidine (BI-MECY-
100, Eurogentec, Belgium) was used for immunopre-
cipitation. The immunoprecipated DNA and sonicated
input DNA were differentially labeled with fluorescent
dyes (Cy3 and Cy5, respectively) and hybridized to
Human DNA Methylation 3x720K CpG Island Plus
RefSeq Promoter Arrays (Roche Nimblegen, Madison,
WI, USA). Acquisition and analysis was performed
using Nimblescan 2.5 and R package DMR provided by
Nimblegen. All data have been deposited into NCBI
GEO GSE57971.
Gene expression analysis
Gene expression datasets were obtained from NCBI
GEO GSE33728 [13], and analysis was performed by R
using the limma package. P values were adjusted by FDR
multiple hypothesis test correction.
Bisulphite sequencing
Genomic DNA was extracted from primary melanoma cell
cultures and subjected to bisulfite (BS) modification (EZ
DNA Methylation Gold Kit, Zymo Research, Irvine, CA,
USA). To validate the DNA methylation status of individual
DNA molecules, we cloned bisulfite-converted PCR frag-
ments into the pCR2.1 vector using the TOPO-TA cloning
kit (Invitrogen, Carlsbad, CA, USA). Individual colonies
were screened for the insert, and the region of interest was
sequenced using M13 primers. A minimum of five clones
were sequenced for each region of interest. Lollipop dia-
grams were generated using BiQ Analyzer [52]. Primers
used for bisulphite PCR are shown in Table 3.
Treatment with decitabine
Decitabine (5-Aza-2′-deoxycytidine, Sigma Chemical
(Aza)) was dissolved in DMSO as a 10 mM stock solution,
aliquoted, and kept at −20°C. Primary melanoma cell
cultures were seeded in Petri dishes (approximately
5,000 cells/cm2) in RPMI untreated or treated with Aza
(5 μM) for 72 h, with fresh drug-supplemented medium
every 24 h.
mRNA expression analysis
Total RNA was isolated using Trizol according to manu-
facturer’s instructions (Invitrogen). In total, 1 μg aliquots
of RNA were reverse transcribed with Reverse Tran-
scription System (Promega) according to the manufac-
turer’s instructions. Data collection and analysis were
performed by ABI Viia7 Fast Real-Time PCR Systems
(Applied Biosystems). Gene expression values of averaged
triplicate reactions were normalized to RPL28 expression
levels. RPL28 primers are as follows: 5′-GCAATTGG
TTCCGCTACAAC-3′ and 5′-TGTTCTTGCGGATCAT
GTGT-3′. The primers for RT-PCR were purchased from
QIAGEN: SOX9 (Hs_SOX9_1_SG).
Western blot
Cells were washed twice with cold phosphate-buffered
saline (PBS) and lysed at 4°C in lysis buffer containing
20 mM Tris–HCl (pH 7.5), 1% Triton X-100 (Sigma-
Aldrich, St Louis, MO, USA), 137 mM NaCl, 10% glycerol,
and protease and phosphatase inhibitors (Roche, Basel,
Switzerland). Proteins were separated by SDS-PAGE
using the NuPAGE SDS-PAGE Gel System (Invitrogen)
under reducing conditions. A total of 15 μg of protein
was mixed with 9 μL of NuPage LDS sample buffer
(4×) (Invitrogen, NP0007), 3.6 μL of NUPAGE Sample
Reducing (Invitrogen, NP0009) and filled up to 36 μL
with RIPA buffer. This mixture was incubated at 85°C
for 10 min while shaking at 900 rpm. Samples were
loaded on NuPage precast gels (Invitrogen). Mem-
branes were probed with the following antibodies:
SOX9 (GTX109661, GeneTex, Hsinchu City, Taiwan);
DNMT1 (ab13537, Abcam, Cambridge, UK); DNMT3a
(ab2850, Abcam, Cambridge, UK); DNMT3b (ab16049,
Table 3 Primers for bisulphite sequencing
Gene Primer Tm
SOX9_1 F: 5′-GGATTGGGGTTTTTTATTTTT-3′ 59°C
R: 5′-TTCAATTTTCTTCCCTTTCCT-3′
SOX9_2 F: 5′-AGGTTATTAGGGTAGATTGGAGG-3′ 59°C
R: 5′5AAATACATATCCCATCACAACC-3′
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Abcam, Cambridge, UK); GAPDH (ab9483, Abcam,
Cambridge, UK);
siRNA knockdown
Silencing RNA (siRNA) transfection of melanoma cells
was carried out using INTERFERin transfection solu-
tion according to the manufacturer’s protocol (Polyplus-
transfection, Illkirch, France). Cells were transfected
with 5 nM of siRNA (Qiagen) for 72 h before RNA or
protein was extracted. As control siRNA, the All-Star
negative siRNA sequence (Qiagen) was used, and gene-
specific siRNAs targeting siSOX9 (SI00007595, SI00007609)
were obtained from Qiagen.
SOX9 lentiviral transfection
Lentiviral particles containing plasmids expressing full-
length SOX9 cDNA or eGFP were transfected into mel-
anoma cells for 48 h. Media supplemented with 4 ng/mL
blasticidin was used for selection. After 1 week of selec-
tion, protein lysate was extracted and analyzed for SOX9
expression. Plasmids for eGFP and SOX9 were a kind
gift from Dr. Thierry Passeron [29].
SOX9 transient transfection
Empty vector or vector containing murine sox9 (a kind
gift from Prof. Lukas Sommer) was transfected into
B16F1 cells with jetPEI (Polyplus, France) according to
manufacturer’s protocol. Protein was isolated at 24 h,
72 h, 144 h, and 288 h after transfection and analyzed
for sox9 expression by western blot.
Microarray and pathway analysis
Gene expression of eGFP and SOX9 transfected cells were
analyzed using the Affymetrix Human Genome U133 Plus
2.0 Array at the Functional Genomics Center Zurich
(FGCZ). Differential gene expression was determined by R
package limma [53]. Pathway analysis was performed
using MetaCore (GeneGo Inc., New York, USA).
Proliferation and cell cycle analysis
For cell cycle analysis, the Click-iT EdU Alexa Fluor 647
Flow Cytometry Assay Kit (Invitrogen) was used. Cells
were labelled with PI according to the manufacturer’s
protocol and the DNA content was measured using a
BD FACSCanto II flow cytometer (BD Biosciences) and
BD FACSDiva software (BD Biosciences). Cell cycle ana-
lysis was performed in triplicate.
Boyden chamber invasion assay
Cells were seeded on FluoroBlok 24-multiwell Insert
System (351157, BD Biosciences) and Biocoat Tumor
Invasion System (354165, BD Biosciences). The invasion
assay was performed as per manufacturer’s instructions.
Migrated and invaded cells were labeled with Calcein AM
fluorescent dye (354216, BD Biosciences) and fluorescence
was measured with Tecan GENios (Tecan, Männendorf,
Switzerland) using 485 nm excitation and 535 nm emis-
sion. Relative invasion was calculated as the ratio of the
fluorescence of invading cells of the Biocoat Tumor
Invasion System divided by the fluorescence of migrating
cells of the FluoroBlok 24-multiwell Insert System. Boyden
chamber assays were performed in triplicate.
Viability assay
Cells were seeded in 24-well microplates at a density of
2 × 104 cells, and cell growth was determined with a
standard colorimetric assay measuring 3-(4,5-dimethyl-
thiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, St Louis, MO, USA) reactivity after 72 h.
MTTassays were performed in triplicate.
Chromatin immunoprecipitation
ChIP analysis was performed as previously described [54].
The Sox9 antibody was from Santa Cruz Biotechnology
(sc-20095, Santa Cruz Biotechnology). Primer sequences
were designed around SOX9 binding motifs [55,56] from
the transcription start site (TSS) to 3 KB upstream of the
TSS. Primers for p21, COL2A1, TMEM158, TBX3, FYB,
SOX10, and IP10 are shown in Table 4.
In vivo metastasis
B16F1 cells were transfected with empty vector or vector
containing murine sox9. 2 × 105 cells were injected intra-
venously into C57BL/6 J mice, five mice per group (Harlan
Laboratories). After 12 days mice were sacrificed and lungs
were examined for metastasis. Statistics were performed
using the Mann–Whitney U test. All animal experiments
have been approved by the veterinary authorities of Canton
Table 4 Primers for ChIP
Genes Primer
COL2A1-F ATCCTCCTTTGTGAGGCTTGTT
COL2A1-R AGTACGAGAGAACCCACTGGAC
p21-F TGATGTGCCACAGTTCACAA
p21-R TCCTGCCAGTTTTCCTGTTC
TMEM158-F TCTGCTGTGTTGGAGCCATT
TMEM158-R GTCTCGCCTTAGTGCTACCG
TBX3-F CTCGCCCCTTTCTTTCCCTT
TBX3-R GGGGGTGTTATGAGCCAACA
FYB-F CTCACATTGCATGGGGACG
FYB-R ATGGGCTTATCACCGGAAGG
SOX10-F CCTCTGCCTCGTGTGACTAC
SOX10-R TCCTGTCTGGAGTGGGCTG-
IP10-F GGGAAATTCCGTAACTTGGA
IP10-R AAGCCATTTTCCCTCCCTAA
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of Zurich, Switzerland, and were performed in accordance
with Swiss law.
TCGA analysis
The SKCM DNA methylation, RNA-seq, and clinical
dataset were downloaded on 28 July 2014 for analysis.
Normalized reads from the level 3 RNA-seq data were
used for analysis. The dataset was segregated into primary
tumors and metastatic tumors for analysis. Chi-squared
test was performed on the clinical parameters between the
SOX9 high and low groups. Differential expression was
analyzed with voom from the limma package [53]. Log
rank test and Cox proportional hazard ratio were analyzed
by the survival R package [57]. DNA methylation β-values
were calculated by minfi [58]. Correlation was calculated
by Spearman’s rank correlation coefficient.
Additional files
Additional file 1: Figure S1. MLANA expression between the
proliferative and invasive phenotype. Ten melanoma cell cultures were
divided into the proliferative and invasive phenotype by expression of
MLANA. GAPDH was used as loading control.
Additional file 2: Table S1. 73 genes with anti-correlative methylation
and gene expression. Analysis of the methylation and expression profiles
of the ten melanoma cell cultures produced this list of significant genes
with a peak score greater than 2 from the MeDIP methylation array and
with a fold change greater than 1 from the gene expression microarray.
Additional file 3: Table S2. Pathway analysis of 73 gene signature.
Genes were uploaded to Metacore and analyzed for significant pathway
enrichment in GO Processes, Process Networks and Pathway Maps.
Additional file 4: Table S3. Differential gene analysis of SOX9
overexpression. Limma output table for differentially expressed genes
between SOX9 overexpression and control M010817 melanoma cells.
Additional file 5: Table S4. Clinical parameters of primary melanoma
patients. TNM stage, gender, and tumor location between the SOX9 high
and SOX9 low patients were evaluated by the Chi-squared test. Age was
evaluated by Student’s t-test. * represents p < 0.05.
Additional file 6: Table S5. Differential gene analysis of SOX9 high and
low primary melanoma patients. Limma output table for SOX9 high
primary melanoma patients versus SOX9 low primary melanoma patients.
Additional file 7: Table S6. Differential gene analysis of SOX9 high and
low metastatic melanoma patients. Limma output table for SOX9 high
metastatic melanoma patients versus SOX9 low metastatic melanoma
patients.
Additional file 8: Table S7. Overlap of SOX9 overexpression and metastatic
melanoma patients. List of genes overlapping from M010817 melanoma cells
overexpressing SOX9 and SOX9 high metastatic melanoma patients.
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